Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AmBev stock logo
ABV
AmBev
$0.00
$0.00
$0.00
N/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$27.81
+0.4%
$26.88
$25.20
$40.37
$157.48B0.6343.15 million shs45.37 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
+1.95%+9.66%+0.54%+2.90%-27.96%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AmBev stock logo
ABV
AmBev
N/AN/AN/AN/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
4.9878 of 5 stars
4.23.04.24.83.11.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AmBev stock logo
ABV
AmBev
N/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.0029.45% Upside

Current Analyst Ratings

Latest PFE and ABV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
2/23/2024
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AmBev stock logo
ABV
AmBev
N/AN/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.69$3.05 per share9.13$15.81 per share1.76

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AmBev stock logo
ABV
AmBev
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B-$0.06N/A10.151.20-0.56%8.58%3.70%8/6/2024 (Estimated)

Latest PFE and ABV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AmBev stock logo
ABV
AmBev
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.04%+2.57%N/A 15 Years

Latest PFE and ABV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AmBev stock logo
ABV
AmBev
N/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AmBev stock logo
ABV
AmBev
N/A
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AmBev stock logo
ABV
AmBev
N/A
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AmBev stock logo
ABV
AmBev
N/AN/AN/ANot Optionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

PFE and ABV Headlines

SourceHeadline
Amgens peek at its GLP-1 drug trial results heightens competition in obesity marketAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
finance.yahoo.com - May 3 at 6:19 PM
Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?
stocknews.com - May 3 at 1:17 PM
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With ExpectationsPfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
msn.com - May 3 at 1:16 PM
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJs New Plan to Resolve Talc ClaimsPharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
finance.yahoo.com - May 3 at 1:16 PM
Vanguard Health Care Funds Strategic Moves in Q1 2024: A Focus on Pfizer IncVanguard Health Care Fund's Strategic Moves in Q1 2024: A Focus on Pfizer Inc
finance.yahoo.com - May 3 at 1:16 PM
Pfizer Inc. (NYSE:PFE) to Post FY2025 Earnings of $2.93 Per Share, Leerink Partnrs ForecastsPfizer Inc. (NYSE:PFE) to Post FY2025 Earnings of $2.93 Per Share, Leerink Partnrs Forecasts
marketbeat.com - May 3 at 12:53 PM
Heres Why Pfizer (PFE) is a Strong Momentum StockHere's Why Pfizer (PFE) is a Strong Momentum Stock
zacks.com - May 3 at 10:56 AM
Great Valley Advisor Group Inc. Trims Stake in Pfizer Inc. (NYSE:PFE)Great Valley Advisor Group Inc. Trims Stake in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 3 at 9:14 AM
NHS to provide Pfizer’s Voxelotor to treat sickle cell diseaseNHS to provide Pfizer’s Voxelotor to treat sickle cell disease
pharmaceutical-technology.com - May 3 at 8:16 AM
Q1 2024 Cardiff Oncology Inc Earnings CallQ1 2024 Cardiff Oncology Inc Earnings Call
finance.yahoo.com - May 3 at 8:16 AM
3 Ultra-Safe Stocks to Buy So You Can Rest Easy in Any Market3 Ultra-Safe Stocks to Buy So You Can Rest Easy in Any Market
investorplace.com - May 3 at 7:00 AM
Pfizer (NYSE:PFE) Shares Up 1.8% on Earnings BeatPfizer (NYSE:PFE) Shares Up 1.8% on Earnings Beat
americanbankingnews.com - May 3 at 2:12 AM
Fifth Third Bancorp Reduces Position in Pfizer Inc. (NYSE:PFE)Fifth Third Bancorp Reduces Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 3 at 12:41 AM
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid declinePfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid decline
msn.com - May 2 at 9:58 PM
Pfizer Prospects Garner Mixed Sentiment From Analysts: Finally, The Pivot Investors Have Been Waiting ForPfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
markets.businessinsider.com - May 2 at 9:58 PM
Pfizer (NYSE:PFE) Announces Quarterly  Earnings ResultsPfizer (NYSE:PFE) Announces Quarterly Earnings Results
marketbeat.com - May 2 at 4:04 PM
Pfizer (NYSE:PFE) Trading Up 1.8% After Better-Than-Expected EarningsPfizer (NYSE:PFE) Trading Up 1.8% After Better-Than-Expected Earnings
marketbeat.com - May 2 at 2:47 PM
Pfizer (NYSE:PFE) Price Target Raised to $29.00Pfizer (NYSE:PFE) Price Target Raised to $29.00
marketbeat.com - May 2 at 1:32 PM
Pfizer Inc. (NYSE:PFE) Q1 2024 Earnings Call TranscriptPfizer Inc. (NYSE:PFE) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 2 at 1:30 PM
BMO Capital Markets Reiterates "Outperform" Rating for Pfizer (NYSE:PFE)BMO Capital Markets Reiterates "Outperform" Rating for Pfizer (NYSE:PFE)
marketbeat.com - May 2 at 11:13 AM
Pfizer Stock: Finally The Market Is Waking UpPfizer Stock: Finally The Market Is Waking Up
seekingalpha.com - May 2 at 8:29 AM
3 Contrarian Stocks That Could Make You a Fortune (If You Dare)3 Contrarian Stocks That Could Make You a Fortune (If You Dare)
investorplace.com - May 2 at 7:22 AM
My Top 5 Favorite High-Yield Dividend Stocks to Buy in MayMy Top 5 Favorite High-Yield Dividend Stocks to Buy in May
fool.com - May 2 at 5:50 AM
Pfizers Stock Is a Buy. Here Are Six Reasons Why.Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
fool.com - May 2 at 5:15 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AmBev logo

AmBev

NYSE:ABV
Companhia de Bebidas das Americas - Ambev (Ambev) is a Brazil-based company. AmBev and its subsidiaries produce, distribute and sell beer, carbonated soft drinks (CSDs) and other non-alcoholic and non-carbonated products in over 15 countries across the Americas. The Company conducts its operations through three business units: Latin America North includes its operations in Brazil, where Ambev operates two divisions: beer sales (Beer Brazil) and carbonated soft drinks and non-alcoholic non-carbonated sales (CSD & NANC Brazil), and its Hispanic Latin America Operations, Excluding Latin America South (HILA-Ex), which includes its operations in the Dominican Republic, Venezuela, Ecuador, Guatemala (which also serves El Salvador and Nicaragua) and Peru; Latin America South includes its operations in Argentina, Bolivia, Paraguay, Uruguay and Chile, and Canada, represented by Labatt's operations includes domestic sales in Canada and some exports to the United States market.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.